{"id":18591,"date":"2025-07-24T08:55:08","date_gmt":"2025-07-24T12:55:08","guid":{"rendered":"https:\/\/www.med.unc.edu\/cfar\/?p=18591"},"modified":"2025-07-24T08:55:08","modified_gmt":"2025-07-24T12:55:08","slug":"a-new-era-in-hiv-prevention-what-lenacapavir-means-for-older-adults","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/cfar\/2025\/07\/a-new-era-in-hiv-prevention-what-lenacapavir-means-for-older-adults\/","title":{"rendered":"A New Era in HIV Prevention: What Lenacapavir Means for Older Adults"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-18594\" src=\"https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy-199x300.jpg\" alt=\"\" width=\"515\" height=\"776\" srcset=\"https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy-199x300.jpg 199w, https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy.jpg 332w\" sizes=\"auto, (max-width: 515px) 100vw, 515px\" \/><\/p>\n<p><span data-contrast=\"none\">A new HIV prevention medication may significantly impact how older adults protect themselves from the virus\u2014and the UNC Center for AIDS Research (CFAR) played a key role in its development.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335559738&quot;:322,&quot;335559739&quot;:322,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">In June, the U.S. Food and Drug Administration (FDA) approved lenacapavir, a long-acting injectable medication marketed as Yeztugo, for use as pre-exposure prophylaxis (PrEP). Unlike current PrEP options\u2014such as daily oral pills like <\/span><i><span data-contrast=\"none\">Truvada<\/span><\/i><span data-contrast=\"none\">, or bimonthly injections like <\/span><i><span data-contrast=\"none\">Apretude<\/span><\/i><span data-contrast=\"none\">\u2014lenacapavir only needs to be administered twice a year. This makes it the most infrequent and potentially most convenient PrEP option available to date. These clinical trials were led by Dr. Joe Eron, Director of the Clinical Core at the UNC CFAR and Co-Director of the Clinical Trials Unit at the UNC Institute for Global Health and Infectious Diseases.\u00a0<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">HIV prevention efforts have traditionally focused on younger populations, but infection rates among adults over 50 have steadily increased in recent years. According to the CDC, nearly 1 in 6 new HIV diagnoses in the U.S. are now among people aged 50 and older. Yet many older adults remain unaware of their risk or are not engaged in preventive care. Lenacapavir\u2019s twice-yearly schedule could remove key barriers for older adults\u2014such as medication fatigue, mobility issues, or lack of routine engagement with HIV care providers. Additionally, its discreet nature may reduce stigma concerns, encouraging more individuals to explore PrEP as a prevention strategy.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">With the approval of lenacapavir, healthcare providers can now offer a broader range of HIV prevention options tailored to individual needs and lifestyles. Older adults who are at risk or have questions about PrEP are encouraged to talk with their healthcare providers about whether this new option is right for them.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new HIV prevention medication may significantly impact how older adults protect themselves from the virus\u2014and the UNC Center for AIDS Research (CFAR) played a key role in its development.\u00a0 In June, the U.S. Food and Drug Administration (FDA) approved lenacapavir, a long-acting injectable medication marketed as Yeztugo, for use as pre-exposure prophylaxis (PrEP). Unlike &hellip; <a href=\"https:\/\/www.med.unc.edu\/cfar\/2025\/07\/a-new-era-in-hiv-prevention-what-lenacapavir-means-for-older-adults\/\" aria-label=\"Read more about A New Era in HIV Prevention: What Lenacapavir Means for Older Adults\">Read more<\/a><\/p>\n","protected":false},"author":120087,"featured_media":18594,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-18591","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","odd"],"acf":[],"featured_image":"https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy-199x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/cfar\/wp-content\/uploads\/sites\/1380\/2025\/07\/eron_joe_donn_web-1-copy.jpg-copy-150x150.jpg","featured_image_alt":"","category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/cfar\/category\/news\/"}],"tag_details":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/posts\/18591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/users\/120087"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/comments?post=18591"}],"version-history":[{"count":2,"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/posts\/18591\/revisions"}],"predecessor-version":[{"id":18595,"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/posts\/18591\/revisions\/18595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/media\/18594"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/media?parent=18591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/categories?post=18591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/cfar\/wp-json\/wp\/v2\/tags?post=18591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}